关注
Navika Shukla
Navika Shukla
未知所在单位机构
在 stanford.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas
BJ Sworder, DM Kurtz, SK Alig, MJ Frank, N Shukla, A Garofalo, ...
Cancer Cell 41 (1), 210-225. e5, 2023
772023
Association between age and nodal metastasis in papillary thyroid carcinoma
N Shukla, N Osazuwa-Peters, UC Megwalu
Otolaryngology–Head and Neck Surgery 165 (1), 43-49, 2021
502021
Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling
SK Alig, M Shahrokh Esfahani, A Garofalo, MY Li, C Rossi, T Flerlage, ...
Nature 625 (7996), 778-787, 2024
412024
Laser interstitial thermal therapy for the treatment of epilepsy: evidence to date
ND Shukla, AL Ho, AV Pendharkar, ES Sussman, CH Halpern
Neuropsychiatric disease and treatment, 2469-2475, 2017
342017
Nectin-1-specific entry of herpes simplex virus 1 is sufficient for infection of the cornea and viral spread to the trigeminal ganglia
ND Shukla, V Tiwari, T Valyi-Nagy
Molecular vision 18, 2711, 2012
322012
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions
A Major, J Yu, N Shukla, Y Che, TG Karrison, R Treitman, MK Kamdar, ...
Blood advances 7 (16), 4528-4538, 2023
202023
Universal screening of gastrointestinal malignancies for mismatch repair deficiency at Stanford
A Abrha, ND Shukla, R Hodan, T Longacre, S Raghavan, CC Pritchard, ...
JNCI Cancer Spectrum 4 (5), pkaa054, 2020
192020
Functional outcomes of septal extension grafting in aesthetic rhinoplasty: a cohort analysis
PN Patel, M Abdelwahab, ND Shukla, H Wadwha, DR Grimm, ...
Facial Plastic Surgery & Aesthetic Medicine 23 (3), 172-179, 2021
152021
The role of insurance status as a mediator of racial disparities in oropharyngeal cancer outcomes
N Shukla, Y Ma, UC Megwalu
Head & Neck 43 (10), 3116-3124, 2021
102021
The cup runneth over: treatment strategies for newly diagnosed acute myeloid leukemia
JH Cooperrider, N Shukla, MT Nawas, AA Patel
JCO Oncology Practice 19 (2), 74-85, 2023
62023
Poor survival outcomes of checkpoint inhibitors for B-cell lymphomas relapsing after or refractory to CAR T-cell therapy: a real-world cohort from 15 US academic institutions
A Major, J Yu, ND Shukla, R Treitman, MK Kamdar, BM Haverkos, ...
Blood 140 (Supplement 1), 1328-1331, 2022
62022
Metastatic Parotid Gland Carcinoma With ERBB2 Amplification With Complete Response to Fam‐Trastuzumab Deruxtecan
ND Shukla, RS Chiang, AD Colevas
Journal of the National Comprehensive Cancer Network 20 (2), 102-104, 2022
42022
DETERMINANTS OF RESISTANCE TO ENGINEERED T‐CELL THERAPIES TARGETING CD19 IN LYMPHOMA
B Sworder, DM Kurtz, S Alig, MJ Frank, CW Macauley, A Garofalo, ...
Hematological Oncology 39, 2021
42021
Functional screening of amplification outlier oncogenes in organoid models of early tumorigenesis
AA Salahudeen, JA Seoane, K Yuki, AT Mah, AR Smith, K Kolahi, M Sean, ...
Cell reports 42 (11), 2023
32023
Profiling T-cell receptor diversity and dynamics during lymphoma immunotherapy using cell-free DNA (cfDNA)
ND Shukla, AFM Craig, B Sworder, DM Kurtz, C Macaulay, A Garofalo, ...
Blood 136, 49-50, 2020
32020
Prevalence and molecular etiology of mismatch repair deficiency among gastrointestinal cancers.
N Shukla, A Abrha, TA Longacre, R Koff, JM Ford, GA Fisher, ...
Journal of Clinical Oncology 37 (4_suppl), 215-215, 2019
32019
Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia
D Gaut, C Oliai, J Boiarsky, S Zhang, A Salhotra, T Azenkot, VE Kennedy, ...
Leukemia & Lymphoma 65 (1), 69-77, 2024
22024
Specificity of immunoglobulin high-throughput sequencing minimal residual disease monitoring in non-Hodgkin lymphomas
ND Shukla, JG Schroers-Martin, BJ Sworder, KR Kathuria, SK Alig, ...
Blood Advances 8 (3), 780-784, 2024
12024
Pan-cancer organoid validation of tumor outlier chromosomal amplification events
AA Salahudeen, K Yuki, JA Seoane, AT Mah, AR Smith, K Kolahi, ...
bioRxiv, 2021.10. 05.463147, 2021
12021
Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy
ND Shukla, AA Salahudeen, GA Taylor, SS Ramalingam, EE Vokes, ...
Clinical lung cancer 19 (5), 377-386, 2018
12018
系统目前无法执行此操作,请稍后再试。
文章 1–20